샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777863

세계의 바이오시밀러 수탁 제조 시장

Biosimilar Contract Manufacturing
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 380 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

바이오시밀러 수탁 제조 세계 시장은 2030년까지 231억 달러에 이를 전망

2024년에 98억 달러로 추정되는 바이오시밀러 수탁 제조 세계 시장은 2030년에는 231억 달러에 이르고, 분석 기간인 2024-2030년 CAGR은 15.5%를 보일 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 재조합 비당화 단백질은 CAGR 17.9%를 나타내고, 분석 기간 종료까지 158억 달러에 이를 것으로 예측됩니다. 재조합 당질화 단백질 부문의 성장률은 분석 기간중 CAGR 11.2%로 추정됩니다.

미국 시장은 27억 달러, 중국은 CAGR 21.0%를 보일 것으로 예측

미국의 바이오시밀러 수탁 제조 시장은 2024년에 27억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 51억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 21.0%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 11.1%와 14.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.4%를 나타낼 전망입니다.

세계의 바이오시밀러 수탁 제조 시장 - 주요 동향과 촉진요인 정리

바이오시밀러 수탁 제조가 바이오의약품 생산의 핵심이 되고 있는 이유는?

바이오시밀러 수탁 제조 시장은 제약회사가 생물학적 제제 대체품을 생산하기 위해 비용 효율적이고 확장 가능한 솔루션을 찾고 있기 때문에 빠르게 성장하고 있습니다. 바이오시밀러는 이미 승인된 오리지널 의약품과 매우 유사한 생물학적 제제로 암, 자가면역질환, 당뇨병 등 만성질환 치료에 사용되는 고가의 생물학적 제제를 대체할 수 있는 보다 저렴한 대안을 제시하는 것입니다. 그러나 바이오시밀러 의약품의 제조에는 고도의 생물학적 전문지식, 규제 대응, 특수 설비가 필요한 복잡한 제조 공정이 필요하기 때문에 많은 제약사들이 CDMO(의약품 개발 및 제조 수탁기관)와 제휴하여 제조의 효율화를 꾀하고 있습니다.

블록버스터 바이오의약품의 특허 만료, 의료기관의 비용 억제책, 바이오시밀러 도입에 대한 규제 당국의 지원 등을 배경으로 바이오시밀러에 대한 수요가 증가함에 따라 고품질 위탁생산 서비스에 대한 요구가 증가하고 있습니다. 바이오시밀러 전문 CDMO는 세포주 개발, 공정 최적화, 대규모 바이오프로세스, 규제 준수 지원 등 엔드 투 엔드 솔루션을 제공합니다. 생물학적 제제의 저렴한 가격과 세계 시장 확대가 강조되는 가운데, 바이오시밀러 수탁 제조는 제약사의 제조비용을 절감하고 접근성을 높이는 데 중요한 역할을 하고 있습니다.

기술 발전이 바이오시밀러 수탁 제조에 어떤 영향을 미치고 있는가?

일회용 시스템, 고처리량 세포주 개발, 공정분석기술(PAT) 등 바이오프로세스기술의 개발이 바이오시밀러 수탁 제조에 혁명을 불러일으키고 있습니다. 가장 중요한 혁신 중 하나는 일회용 바이오리액터를 채택하여 오염 위험과 운영 비용을 최소화하면서 유연하고 확장 가능한 생산을 가능하게 하는 것입니다. 이러한 바이오리액터를 통해 CDMO는 시장 수요에 따라 생산 능력을 신속하게 조정할 수 있어 효율성을 높이고 생산 소요 시간을 단축할 수 있습니다.

바이오시밀러 제조의 또 다른 큰 혁신은 공정 최적화에 인공지능(AI)과 머신러닝(ML)을 통합한 것입니다. CDMO는 AI를 활용한 예측 분석을 통해 바이오프로세스 조건을 미세 조정하고, 수율을 개선하고, 배치 간 일관성을 보장할 수 있습니다. 또한, 고해상도 질량 분석 및 바이오 분석 등 바이오시밀러 특성 평가 기술의 발전으로 바이오시밀러와 기준 생물학적 제제와의 비교 가능성 평가가 향상되고 있습니다. 또한, 연속적인 바이오프로세스의 채택은 실시간 모니터링을 가능하게 하고, 기존 배치 공정에 비해 제조 비용을 절감하는 등 업계에도 변화를 가져왔습니다. 이러한 기술 발전으로 바이오시밀러의 제조 효율이 지속적으로 향상되고 있는 가운데, 위탁생산 업체들은 시장 진입을 가속화하고 고품질 제조 기준을 유지하고자 하는 제약사의 전략적 파트너로서 입지를 더욱 강화하고 있습니다.

바이오시밀러 수탁 제조의 성장을 견인하는 시장 동향은?

비용 효율적인 바이오의약품에 대한 수요 증가와 세계 헬스케어 시장에서 바이오시밀러에 대한 수용성 확대는 바이오시밀러 수탁 제조 분야의 성장을 견인하는 주요 트렌드입니다. 산업을 형성하는 가장 중요한 트렌드 중 하나는 특히 종양학, 면역학, 내분비학, 혈액학 분야에서 바이오시밀러 제품 파이프라인이 확대되고 있다는 점입니다. 블록버스터 바이오의약품의 특허가 여러 건 만료됨에 따라 제약사들은 바이오시밀러를 대체할 수 있는 의약품 개발에 박차를 가하고 있으며, 신뢰성과 확장성이 뛰어난 위탁생산 솔루션에 대한 필요성이 높아지고 있습니다.

시장을 형성하는 또 다른 주요 트렌드는 신흥 시장에서의 바이오시밀러 채택 확대와 각국 정부가 저렴한 바이오의약품에 대한 접근성을 개선하기 위한 정책을 시행하고 있다는 점입니다. 중국, 인도, 브라질 등의 국가에서는 바이오시밀러 의약품의 승인이 증가하고 현지 바이오의약품 인프라에 대한 투자도 증가함에 따라 CDMO는 각 지역에 제조시설을 설립하고 있습니다. 또한, 하이브리드 제조 모델(제약회사가 세포주 개발, 충진 서비스 등 바이오시밀러 제조의 특정 분야만 아웃소싱하는 모델)의 등장으로 제조 파트너십에 유연성을 부여하고 있습니다. FDA, EMA 등 규제 당국도 승인 절차 간소화를 통해 바이오시밀러 의약품의 채택을 지원하고 있으며, 이는 시장 성장을 더욱 촉진하고 있습니다.

바이오시밀러 수탁 제조 시장의 미래를 좌우할 주요 성장 동력은?

바이오시밀러 수탁 제조 시장의 성장은 규제 당국의 지원 증가, 헬스케어 시스템에 대한 비용 압박, 바이오시밀러 포트폴리오의 확대 등 여러 요인에 의해 이루어지고 있습니다. 주요 성장 요인 중 하나는 제약기업이 엄격한 규제 요건을 준수하면서 개발 및 제조 비용을 절감할 필요가 있다는 점입니다. 위탁생산을 통해 바이오제약기업은 전문적 전문지식, 최첨단 인프라, 규제 관련 지식을 활용할 수 있으며, 자체 생산에 따른 위험과 비용을 최소화할 수 있습니다.

시장을 형성하는 또 다른 중요한 요소는 전략적 제휴와 파트너십의 역할 증가입니다. 주요 제약사들은 CDMO와 협력하여 공급망 효율성을 최적화하면서 바이오시밀러의 상용화를 가속화하고 있습니다. 또한, 바이오시밀러 수탁 제조과 맞춤형 의료 및 차세대 생물학적 제제와의 융합이 진행되어 새로운 혁신의 기회가 창출되고 있습니다. 바이오시밀러에 대한 수요가 증가하고 제조 기술이 계속 발전함에 따라, 위탁생산 기관은 바이오의약품 산업 전반에 걸쳐 세계 바이오시밀러에 대한 접근성 확대, 고품질 제조 보장, 비용 효율성 증진에 있어 더욱 큰 역할을 할 준비가 되어 있습니다.

부문

제품 유형(재조합 비글리코실화 단백질, 재조합 글리코실화 단백질), 생산기술(포유류 기술, 비포유류 기술), 용도(종양학 용도, 혈액 질환 용도, 성장호르몬 결핍증 용도, 만성 및 자가면역질환 용도, 류마티스 관절염 용도, 기타 용도)

조사 대상 기업 예

  • AGC Biologics
  • Alcami Corporation Inc.
  • Almac Group
  • Avid Bioservices, Inc.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Cell Therapies Pty Ltd
  • Charles River Laboratories International, Inc.
  • Element Materials Technology
  • FujiFilm Diosynth Biotechnologies U.S.A., Inc.
  • Fujifilm Kyowa Kirin Biologics Co., Ltd.
  • IQVIA, Inc.
  • KBI Biopharma
  • Kemwell Biopharma Pvt., Ltd.
  • Miltenyi Biotec GmbH
  • Minaris Regenerative Medicine
  • Rentschler Biopharma SE
  • Samsung BioLogics Co., Ltd.
  • Thermo Fisher Scientific, Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.06

Global Biosimilar Contract Manufacturing Market to Reach US$23.1 Billion by 2030

The global market for Biosimilar Contract Manufacturing estimated at US$9.8 Billion in the year 2024, is expected to reach US$23.1 Billion by 2030, growing at a CAGR of 15.5% over the analysis period 2024-2030. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$15.8 Billion by the end of the analysis period. Growth in the Recombinant Glycosylated Proteins segment is estimated at 11.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 21.0% CAGR

The Biosimilar Contract Manufacturing market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.1 Billion by the year 2030 trailing a CAGR of 21.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 14.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Biosimilar Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Biosimilar Contract Manufacturing Becoming a Cornerstone of Biopharmaceutical Production?

The biosimilar contract manufacturing market is witnessing rapid growth as pharmaceutical companies seek cost-effective and scalable solutions to produce biologic alternatives. Biosimilars, which are biologic medicines highly similar to already approved reference drugs, offer a more affordable alternative to expensive biologics used in treating chronic diseases such as cancer, autoimmune disorders, and diabetes. However, the complex manufacturing processes involved in biosimilar production-requiring advanced biologic expertise, regulatory compliance, and specialized facilities-have led many pharmaceutical companies to partner with contract development and manufacturing organizations (CDMOs) to streamline production.

The rising demand for biosimilars, driven by patent expirations of blockbuster biologics, cost-containment measures by healthcare providers, and regulatory support for biosimilar adoption, has fueled the need for high-quality contract manufacturing services. CDMOs specializing in biosimilars provide end-to-end solutions, including cell line development, process optimization, large-scale bioprocessing, and regulatory compliance support. With the growing emphasis on biologics affordability and global market expansion, biosimilar contract manufacturing is playing a crucial role in enhancing accessibility while reducing production costs for pharmaceutical companies.

How Are Technological Advancements Enhancing Biosimilar Contract Manufacturing?

Advancements in bioprocessing technologies, including single-use systems, high-throughput cell line development, and process analytical technology (PAT), are revolutionizing biosimilar contract manufacturing. One of the most significant innovations is the adoption of single-use bioreactors, which allow flexible and scalable production while minimizing contamination risks and operational costs. These bioreactors enable CDMOs to quickly adjust production capacities based on market demand, improving efficiency and reducing manufacturing turnaround times.

Another major breakthrough in biosimilar manufacturing is the integration of artificial intelligence (AI) and machine learning (ML) in process optimization. AI-driven predictive analytics enable CDMOs to fine-tune bioprocessing conditions, enhance yield, and ensure batch-to-batch consistency. Additionally, advancements in biosimilar characterization techniques, such as high-resolution mass spectrometry and bioassays, are improving the comparability assessment between biosimilars and their reference biologics. The adoption of continuous bioprocessing is also transforming the industry, allowing for real-time monitoring and reducing production costs compared to traditional batch processing. As these technological advancements continue to enhance biosimilar manufacturing efficiency, contract manufacturers are increasingly becoming strategic partners for pharmaceutical companies looking to accelerate market entry and maintain high-quality production standards.

Which Market Trends Are Driving the Growth of Biosimilar Contract Manufacturing?

The rising demand for cost-effective biologics and the increasing acceptance of biosimilars in global healthcare markets are major trends fueling the biosimilar contract manufacturing sector. One of the most significant trends shaping the industry is the growing pipeline of biosimilar products, particularly in oncology, immunology, endocrinology, and hematology. With multiple patents on blockbuster biologics expiring, pharmaceutical companies are racing to develop biosimilar alternatives, driving the need for reliable and scalable contract manufacturing solutions.

Another key trend shaping the market is the expansion of biosimilar adoption in emerging markets, where governments are implementing policies to improve access to affordable biologics. Countries such as China, India, and Brazil are witnessing increased biosimilar approvals and investments in local biopharmaceutical infrastructure, prompting CDMOs to establish regional production facilities. Additionally, the rise of hybrid manufacturing models-where pharmaceutical companies outsource only specific segments of biosimilar production, such as cell line development or fill-finish services-is providing flexibility in manufacturing partnerships. Regulatory agencies, including the FDA and EMA, are also supporting biosimilar adoption through streamlined approval pathways, further driving market growth.

What Are the Key Growth Drivers Shaping the Future of the Biosimilar Contract Manufacturing Market?

The growth in the biosimilar contract manufacturing market is driven by multiple factors, including increasing regulatory support, cost pressures on healthcare systems, and the expansion of biosimilar portfolios. One of the primary growth drivers is the need for pharmaceutical companies to reduce development and production costs while maintaining compliance with stringent regulatory requirements. Contract manufacturing allows biopharma firms to leverage specialized expertise, state-of-the-art infrastructure, and regulatory knowledge, minimizing the risks and expenses associated with in-house biologics production.

Another crucial driver shaping the market is the increasing role of strategic collaborations and partnerships. Large pharmaceutical companies are forming alliances with CDMOs to accelerate biosimilar commercialization while optimizing supply chain efficiency. Additionally, the growing integration of biosimilar contract manufacturing with personalized medicine and next-generation biologics is opening new opportunities for innovation. As the demand for biosimilars continues to rise and manufacturing technologies evolve, contract manufacturing organizations are poised to play an even greater role in expanding global biosimilar accessibility, ensuring high-quality production, and driving cost efficiency across the biopharmaceutical industry.

SCOPE OF STUDY:

The report analyzes the Biosimilar Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins); Production Technology (Mammalian Technology, Non-Mammalian Technology); Application (Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic and Autoimmune Disorders Application, Rheumatoid Arthritis Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AGC Biologics
  • Alcami Corporation Inc.
  • Almac Group
  • Avid Bioservices, Inc.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Cell Therapies Pty Ltd
  • Charles River Laboratories International, Inc.
  • Element Materials Technology
  • FujiFilm Diosynth Biotechnologies U.S.A., Inc.
  • Fujifilm Kyowa Kirin Biologics Co., Ltd.
  • IQVIA, Inc.
  • KBI Biopharma
  • Kemwell Biopharma Pvt., Ltd.
  • Miltenyi Biotec GmbH
  • Minaris Regenerative Medicine
  • Rentschler Biopharma SE
  • Samsung BioLogics Co., Ltd.
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biosimilar Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Demand for Affordable Biologics Throws the Spotlight on Biosimilar Contract Manufacturing Services
    • Patent Expiry of Blockbuster Biologics Drives Market Expansion for Biosimilar Development and Manufacturing Partnerships
    • Cost-Efficiency Pressures Among Biosimilar Developers Strengthen the Business Case for Outsourced Manufacturing Models
    • Growing Pipeline of Biosimilars Across Therapeutic Areas Expands Addressable Market Opportunity for CDMOs
    • Shift Toward Flexible and Scalable Biomanufacturing Platforms Fuels Investment in Single-Use and Modular Facilities
    • Emerging Biotech Firms and Startups Leverage CDMO Capabilities to Fast-Track Biosimilar Product Development
    • Rising Complexity in Biosimilar Analytical and Formulation Requirements Spurs Demand for Specialized Manufacturing Expertise
    • Globalization of Biosimilar Markets Drives Need for Regionally Compliant and GMP-Certified Contract Manufacturing Facilities
    • Technological Advancements in Upstream and Downstream Bioprocessing Enhance Efficiency and Scalability of CDMO Operations
    • Increased Focus on Time-to-Market Advantage Creates Opportunities for End-to-End Integrated CDMO Services
    • Expansion of Multi-Product Facilities by CDMOs Strengthens Flexibility for Multi-Client Biosimilar Production
    • Growing Demand for Fill-Finish Capabilities and Late-Stage Manufacturing Support Drives Facility Upgrades
    • Rising Investment in Emerging Markets and Low-Cost Production Hubs Opens New Avenues for Global Biosimilar Manufacturing Outsourcing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biosimilar Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Biosimilar Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Biosimilar Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Recombinant Non-glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Recombinant Non-glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Recombinant Non-glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Recombinant Glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Recombinant Glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Blood Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Blood Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Blood Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Growth Hormonal Deficiency Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Growth Hormonal Deficiency Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Growth Hormonal Deficiency Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Chronic & Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Chronic & Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Chronic & Autoimmune Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Rheumatoid Arthritis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Mammalian Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Mammalian Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Mammalian Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Non-Mammalian Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Non-Mammalian Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Non-Mammalian Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • JAPAN
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • CHINA
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • EUROPE
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Biosimilar Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • FRANCE
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • GERMANY
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • INDIA
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Biosimilar Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Biosimilar Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030
  • AFRICA
    • Biosimilar Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Biosimilar Contract Manufacturing by Product Type - Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Biosimilar Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Biosimilar Contract Manufacturing by Application - Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Biosimilar Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Blood Disorders Application, Growth Hormonal Deficiency Application, Chronic & Autoimmune Disorders Application and Rheumatoid Arthritis Application for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Biosimilar Contract Manufacturing by Production Technology - Mammalian Technology and Non-Mammalian Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Biosimilar Contract Manufacturing by Production Technology - Percentage Breakdown of Value Sales for Mammalian Technology and Non-Mammalian Technology for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제